Skip to content
Discover J&J
Medicines & therapies
Medical devices & technology
Discover J&J
Medicines & therapies
Medical devices & technology
Center for
U.S. Healthcare
Policy Research
Research
areas
Research areas
Value
Access
Innovation
All content
Transparency Report
& Issue Briefs
Perspectives
& insights
About us
Menu
Center for
U.S. Healthcare
Policy Research
Research
areas
Research areas
Value
Access
Innovation
All content
Transparency Report
& Issue Briefs
Perspectives
& insights
About us
Show Search
Search Query
Clear
Submit Search
Dictate search request
Listening...
Search Results
No Results
See all results
Sorry, I don't understand. Please try again
Search results
Search Query
Submit Search
Listening...
There are 111 results that match your search.
Access
October 9, 2025
Does the 340B Program unintentionally reinforce patterns of hospital consolidation in the United States?
Research presented at the 2025 ISPOR Conference offers a new perspective on this issue.
Read more
Transparency Report & Issue Briefs
America’s intellectual property system
The backbone of patient access to critical medicines
Read more
Perspectives & insights
October 27, 2025
Are chronic disease patients being left behind?
Read more
Perspectives & insights
October 27, 2025
Research highlights the arbitrary nature of thresholds in cost-effectiveness analysis
Read more
Value
October 27, 2025
Are cost-effectiveness analysis thresholds fit for purpose for U.S. decision-making?
Read more
Perspectives & insights
October 27, 2025
Data-driven Senate hearing underscores bipartisan support for 340B reform
Read more
Access
Influence of Prescription Drug Affordability Boards and Upper Payment Limits on state drug pricing
Read more
Value
Understanding state Medicaid spending on prescription drugs
This analysis demonstrates that state Medicaid programs are estimated to be spending near or below the national average on prescription drugs.
Read more
Perspectives & insights
November 3, 2025
Why state price control efforts on prescription drugs are missing the mark
Read more
Value
November 3, 2025
Are state prescription drug affordability boards (PDABs) and upper payment limits (UPLs) achieving their intended goals?
Read more
8 of 12
